HCV and Serum Proteome
Hepatitis C virologic response predicted using serum proteome
A study from France has reported on the use of the serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin.
"Surface-enhanced laser desorption ionization time-of-flight mass spectrometry is a proteomic technique that enables the global profiling of proteins. We used this approach to monitor the kinetics of serum proteome in patients with chronic hepatitis C virus infection receiving a standard bitherapy regimen to predict treatment response," wrote V. Paradis and colleagues, Department of Pathology.
They explained. "Ninety-six patients with chronic hepatitis C were retrospectively selected. All patients received complete treatment with pegylated interferon in combination with ribavirin. Patients had serum sampling before starting treatment and at the end of treatment. Results were validated in an independent cohort of 5:1 patients."
"Comparison of protein profiles in pretreatment and after-treatment serum allowed us to characterize 50 protein peaks, the level of which significantly varied. In the group of patients with sustained virologic response, 37 peaks displayed significant variation during treatment, whereas only one peak differed in nonresponders.
"A logistic regression analysis allowed us to define an algorithm composed of 2 protein peaks (fibrosis stage and genotype) that correctly predicted, in pretreatment serum, response to treatment in 89% of all patients with an area under the receiver operating characteristic curve of 0.92," the investigators wrote.
"In the independent testing group, the same difference in proteome kinetics was observed between sustained responders and nonresponders. The algorithm correctly predicted treatment response in 81% of patients in the testing group," the scientists observed.
They concluded, "This study suggests that the kinetics of proteome are significantly different in serum of patients according to treatment response. Serum protein profiling allows prediction of response to antiviral treatment in a significant proportion of patients."
Paradis and colleagues published their study in Gastroenterology (Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology, 2006;130(7):2189-2197).
For more information, contact V. Paradis, Department of Pathology, Clichy, France.
Publisher contact information for the journal Gastroenterology is: W B Saunders Co-Elsevier Inc., Independence Square West Curtis Center, Ste. 300, Philadelphia, PA 19106-3399, USA.
A study from France has reported on the use of the serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin.
"Surface-enhanced laser desorption ionization time-of-flight mass spectrometry is a proteomic technique that enables the global profiling of proteins. We used this approach to monitor the kinetics of serum proteome in patients with chronic hepatitis C virus infection receiving a standard bitherapy regimen to predict treatment response," wrote V. Paradis and colleagues, Department of Pathology.
They explained. "Ninety-six patients with chronic hepatitis C were retrospectively selected. All patients received complete treatment with pegylated interferon in combination with ribavirin. Patients had serum sampling before starting treatment and at the end of treatment. Results were validated in an independent cohort of 5:1 patients."
"Comparison of protein profiles in pretreatment and after-treatment serum allowed us to characterize 50 protein peaks, the level of which significantly varied. In the group of patients with sustained virologic response, 37 peaks displayed significant variation during treatment, whereas only one peak differed in nonresponders.
"A logistic regression analysis allowed us to define an algorithm composed of 2 protein peaks (fibrosis stage and genotype) that correctly predicted, in pretreatment serum, response to treatment in 89% of all patients with an area under the receiver operating characteristic curve of 0.92," the investigators wrote.
"In the independent testing group, the same difference in proteome kinetics was observed between sustained responders and nonresponders. The algorithm correctly predicted treatment response in 81% of patients in the testing group," the scientists observed.
They concluded, "This study suggests that the kinetics of proteome are significantly different in serum of patients according to treatment response. Serum protein profiling allows prediction of response to antiviral treatment in a significant proportion of patients."
Paradis and colleagues published their study in Gastroenterology (Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology, 2006;130(7):2189-2197).
For more information, contact V. Paradis, Department of Pathology, Clichy, France.
Publisher contact information for the journal Gastroenterology is: W B Saunders Co-Elsevier Inc., Independence Square West Curtis Center, Ste. 300, Philadelphia, PA 19106-3399, USA.
0 comments:
Post a Comment